PressJune 7, 2024 Red Light Holland Announces Completion of Full Psilocybin Extraction Report with PharmAla
PressJune 5, 2024 Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
PressJune 4, 2024 Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
PressJune 3, 2024 Filament Health Announces Warrant Exercise and Note Conversion by Negev Capital and Concurrent Private Placement of Common Shares to Benjamin Lightburn, Chief Executive Officer
PressJune 3, 2024 Filament Health Announces Authorization of Phase 2 Clinical Trial for PEX010 in the Treatment of Methamphetamine Use Disorder
PressJune 3, 2024 Wesley Ramjeet to Join Lobe Sciences’ Board of Directors, Bringing Decades of Strategic Financial Expertise
PressJune 3, 2024 Numinus Wellness Announces Voting Results From its Annual General Meeting of Shareholders
PressMay 31, 2024 atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
PressMay 30, 2024 Numinus and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder
PressMay 30, 2024 Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
PressMay 30, 2024 Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors
PressMay 30, 2024 Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy
PressMay 29, 2024 Red Light Holland Initiates Psilocybin Extraction Phase with PharmAla Following Successful Testing and Preparation by CCrest Labs
PressMay 29, 2024 Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
